Enliven Therapeutics, Inc. – NASDAQ:ELVN
Enliven Therapeutics stock price today
$19.76
-2.60
-11.67%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 4 hours
Enliven Therapeutics stock price monthly change
-9.58%
month
Enliven Therapeutics stock price quarterly change
-9.58%
quarter
Enliven Therapeutics stock price yearly change
+50.94%
year
Enliven Therapeutics key metrics
Market Cap | 1.05B |
Enterprise value | N/A |
P/E | -22.72 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 5.69 |
PEG ratio | -0.22 |
EPS | -1.93 |
Revenue | N/A |
EBITDA | -92.79M |
Income | -79.59M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEnliven Therapeutics stock price history
Enliven Therapeutics stock forecast
Enliven Therapeutics financial statements
Average Price Target
$39.5
Potential upside: 99.89%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -16.72M | |
|---|---|---|---|
| Sep 2023 | 0 | -20.76M | |
| Dec 2023 | 440K | -19.37M | -4402.27% |
| Mar 2024 | 0 | -22.73M |
| Jun 2023 | 288501000 | 9.50M | 3.3% |
|---|---|---|---|
| Sep 2023 | 274041000 | 12.29M | 4.49% |
| Dec 2023 | 271867000 | 25.96M | 9.55% |
| Mar 2024 | 342777000 | 25.06M | 7.31% |
| Jun 2023 | -12.04M | -151.51M | -2.82M |
|---|---|---|---|
| Sep 2023 | -15.89M | -35.54M | -425K |
| Dec 2023 | -12.48M | 38.68M | 90K |
| Mar 2024 | -23.36M | -17.88M | 90.27M |
Enliven Therapeutics alternative data
| Aug 2023 | 29 |
|---|---|
| Sep 2023 | 37 |
| Oct 2023 | 37 |
| Nov 2023 | 37 |
| Dec 2023 | 44 |
| Jan 2024 | 44 |
| Feb 2024 | 44 |
| Mar 2024 | 46 |
| Apr 2024 | 46 |
| May 2024 | 46 |
| Jun 2024 | 50 |
| Jul 2024 | 50 |
Enliven Therapeutics other data
13.78%
+13.78%
of ELVN is owned by hedge funds
19
+19
3.63M
+3.63M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 533395 |
| Feb 2024 | 0 | 846395 |
| Mar 2024 | 0 | 34673 |
| Apr 2024 | 0 | 254020 |
| May 2024 | 0 | 2103362 |
| Jun 2024 | 0 | 18653 |
| Jul 2024 | 0 | 104231 |
| Aug 2024 | 0 | 29520 |
| Sep 2024 | 0 | 7520 |
| Oct 2024 | 0 | 146319 |
| Nov 2024 | 0 | 5250 |
| Quarter | Transcript |
|---|---|
| Q4 2021 15 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 9 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 8 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 11 May 2021 | Q1 2021 Earnings Call Transcript |
-
What's the price of Enliven Therapeutics stock today?
One share of Enliven Therapeutics stock can currently be purchased for approximately $19.76.
-
When is Enliven Therapeutics's next earnings date?
Unfortunately, Enliven Therapeutics's (ELVN) next earnings date is currently unknown.
-
Does Enliven Therapeutics pay dividends?
No, Enliven Therapeutics does not pay dividends.
-
How much money does Enliven Therapeutics make?
Enliven Therapeutics has a market capitalization of 1.05B.
-
What is Enliven Therapeutics's stock symbol?
Enliven Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ELVN".
-
What is Enliven Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Enliven Therapeutics?
Shares of Enliven Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Enliven Therapeutics have?
As Jul 2024, Enliven Therapeutics employs 50 workers, which is 9% more then previous quarter.
-
When Enliven Therapeutics went public?
Enliven Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 12 Mar 2020.
-
What is Enliven Therapeutics's official website?
The official website for Enliven Therapeutics is enliventherapeutics.com.
-
Where are Enliven Therapeutics's headquarters?
Enliven Therapeutics is headquartered at 6200 Lookout Road, Boulder, CO.
-
How can i contact Enliven Therapeutics?
Enliven Therapeutics's mailing address is 6200 Lookout Road, Boulder, CO and company can be reached via phone at +7 206478519.
-
What is Enliven Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Enliven Therapeutics in the last 12 months, the avarage price target is $39.5. The average price target represents a 99.89% change from the last price of $19.76.
Enliven Therapeutics company profile:
Enliven Therapeutics, Inc.
enliventherapeutics.comExchange:
NASDAQ
Full time employees:
46
Industry:
Biotechnology
Sector:
Healthcare
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
6200 Lookout Road
Boulder, CO 80301
Boulder, CO 80301
CIK: 0001672619
ISIN: US29337E1029
CUSIP: 29337E102
